180 Life Sciences Says Co, Regulatory Team Met With MHRA To Propose Path Forward For Approval Of Co's Use Of Adalimumab As Anti-TNF Therapy; In Response, MHRA Agreed With Co's Proposed Primary And Secondary Endpoints For A Proposed Phase 3 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
180 Life Sciences has met with the Medicines and Healthcare products Regulatory Agency (MHRA) to propose a path forward for the approval of the company's use of Adalimumab as an anti-TNF therapy. The MHRA has agreed with the company's proposed primary and secondary endpoints for a proposed Phase 3 clinical trial.
October 18, 2023 | 8:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The MHRA's agreement with 180 Life Sciences' proposed endpoints for a Phase 3 clinical trial of Adalimumab could potentially accelerate the approval process for the drug, potentially positively impacting the company's stock.
The MHRA's agreement with the proposed endpoints for the Phase 3 clinical trial could potentially streamline the approval process for Adalimumab. This could lead to earlier market entry for the drug, potentially increasing revenues and positively impacting the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100